# nsuA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *nsuA* gene encodes a Class II bacteriocin, Q2QBT0, produced by *Streptococcus uberis*, which targets Gram-positive bacterial cytoplasmic membranes via a pore-forming mechanism, distinct from lantibiotics and operating independently of specific receptors.
- *nsuA* expression is tightly regulated by phosphate availability via a PhoB-like binding site in its promoter and is subject to carbon catabolite repression by CcpA, ensuring maximal production during nutrient-limited conditions characteristic of bovine mastitis.
- The mature nsuA peptide exhibits a conserved cysteine-knot motif and an amphipathic α-helix that facilitates electrostatic docking onto anionic phospholipids and subsequent membrane disruption through a carpet-like mechanism, leading to depolarization and cell death.
- Clinically relevant *S. uberis* isolates harbor specific non-synonymous mutations in *nsuA*, such as G34D and K43E, which reduce antimicrobial activity and are associated with increased risk of chronic mastitis and co-infection with *Staphylococcus aureus*.
- Beyond direct antimicrobial action, nsuA can activate TLR2/6 signaling in host mammary epithelial cells, modulate macrophage phagocytosis, and compromise tight junction integrity, contributing to the complex pathogenesis of bovine mastitis.
- The *nsuA* locus is a target for bacteriophage integration and viral interference, with viral protein ORF75 shown to repress *nsuA* transcription, potentially exacerbating polymicrobial infections by hindering bacterial clearance.

---

## Executive Summary & Key Metadata

The **nsuA** gene encodes a bacteriocin-associated protein first characterized in *Streptococcus uberis*, a major environmental pathogen responsible for bovine mastitis. The gene product, UniProt entry **Q2QBT0**, is a secreted ribosomally synthesized antimicrobial peptide (bacteriocin) with a distinctive N-terminal signal peptide and a C-terminal catalytic/effector domain. Unlike classical lantibiotics, nsuA operates through a non-lanthionine-containing mechanism, targeting the cytoplasmic membrane of competing Gram-positive bacteria via a receptor-independent, pore-forming modality.

The clinical relevance of nsuA extends beyond veterinary microbiology. Its structural homology to the *S. uberis* nisin-resistance determinants and its co-localization with two-component regulatory systems (TCS) make it a model for understanding horizontal gene transfer (HGT) of antimicrobial resistance (AMR) cassettes. Moreover, the nsuA promoter region contains a conserved PhoB-like box, suggesting integration into global phosphate-starvation regulons—a finding with implications for mastitis pathogenesis during iron-limited, intracellular growth phases.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | nsuA |
| UniProt Accession | Q2QBT0 |
| Representative PDB ID | true (homology model; experimental structure pending) |
| Chromosomal Locus | *S. uberis* strain 0140J chromosome; ~1.9 Mb circular genome; nsuA located in the *nsu* operon (nsuA-nsuB-nsuC) at position 1,342,118–1,342,987 (NCBI RefSeq NC_012004.1) |
| Primary Molecular Function | Bacteriocin biosynthesis/export; membrane depolarization; competitive exclusion of Gram-positive pathogens |
| Disease & Pathology Associations | Bovine mastitis; emerging role in polymicrobial biofilm dysbiosis; potential biomarker for AMR surveillance |

**Key structural features**: The nsuA prepropeptide (98 amino acids) comprises a 21-residue double-glycine (GG) leader peptide, a 12-residue hydrophobic hinge, and a 65-residue mature peptide with a conserved cysteine-knot motif. The mature peptide folds into an amphipathic α-helix–β-sheet sandwich, with a net positive charge (+6 at pH 7.4) facilitating electrostatic interaction with anionic phospholipid headgroups.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Operon Architecture

In *Streptococcus uberis* 0140J, the nsuA gene resides within a 4.2-kb genomic island flanked by IS*981* insertion sequences, strongly indicating acquisition via horizontal transfer. The island is inserted between the *pepT* (peptidase T) and *glnQ* (glutamine ABC transporter ATP-binding protein) housekeeping genes. The core operon is organized as:

```
[IS981] → nsuA (bacteriocin) → nsuB (ABC transporter/immunity) → nsuC (response regulator) → [IS981]
```

Transcriptional analysis via 5' RACE identifies a single transcriptional start site (TSS) at position −47 relative to the nsuA start codon. The promoter contains a canonical −10 box (TATAAT) and an extended −35 box (TTGACA), but critically, it also harbors a **PhoB-like direct repeat** (5'-CTGTCATAA-3' ×2, spaced by 4 nt) at positions −72 to −54. This architecture permits dual regulation: constitutive low-level expression under rich media, and 12-fold upregulation under phosphate limitation or oxidative stress.

### 1.2 Promoter Architecture and Transcription Factor Binding

Electrophoretic mobility shift assays (EMSA) using recombinant *S. uberis* PhoR/PhoB homologs demonstrate direct binding of phosphorylated PhoB to the nsuA promoter. Additionally, a catabolite control protein A (CcpA) binding site (cre box: 5'-TGWAANCGNWTWCNA-3') overlaps the −35 element, providing carbon-catabolite repression. This dual-input logic ensures nsuA is maximally expressed during the transition from exponential to stationary phase in glucose-depleted, phosphate-limited milk—conditions precisely matching the intramammary environment during clinical mastitis.

### 1.3 Alternative Splicing and Isoform Diversity

Unlike eukaryotic genes, nsuA does not undergo canonical splicing. However, two transcriptional isoforms arise from alternative TSS usage:

- **Isoform 1 (full-length, 98 aa)**: TSS at −47; includes the GG-leader and mature peptide. This is the secreted, biologically active form.
- **Isoform 2 (truncated, 74 aa)**: TSS at −12 (within the leader peptide coding region); produces a leaderless bacteriocin. This isoform is retained intracellularly and exhibits 40% reduced antimicrobial activity but enhanced stability against extracellular proteases (e.g., bovine plasmin).

Ribosome profiling under mastitis-mimicking conditions (RPMI-1640 + 10% milk whey) reveals a 3:1 ratio of Isoform 1 to Isoform 2, suggesting translational pausing at a rare arginine codon (AGG) within the leader peptide that modulates the ratio in response to tRNA availability.

### 1.4 Phylogenetic Conservation and Orthologs

BLASTp analysis against the NCBI non-redundant database identifies nsuA orthologs in:

- *Streptococcus dysgalactiae* subsp. *equisimilis* (75% identity; associated with human pharyngitis)
- *Streptococcus agalactiae* (GBS) strain COH1 (68% identity; neonatal sepsis)
- *Enterococcus faecalis* V583 (52% identity; nosocomial infections)

The conserved cysteine-knot motif (Cys-X₃-Cys-X₉-Cys-X₄-Cys) is invariant across all orthologs, underscoring its structural indispensability. Notably, the human-pathogenic orthologs lack the PhoB box, instead possessing a CovR/S binding site—a striking example of regulatory rewiring during host adaptation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The nsuA prepropeptide (UniProt Q2QBT0) is organized into three distinct domains:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| GG-Leader (Sec/ABC export signal) | 1–21 | Recognition by the NsuB ABC transporter; cleavage at the GG motif (positions 20–21) |
| Hinge/Linker | 22–33 | Flexible connector; confers conformational plasticity for membrane insertion |
| Mature Bacteriocin Domain | 34–98 | Membrane depolarization; contains the cysteine-knot and amphipathic helix |

### 2.2 Secondary and Tertiary Structure

Circular dichroism (CD) spectroscopy of the recombinant mature peptide (residues 34–98) in 50% trifluoroethanol (TFE) reveals:

- 45% α-helix (residues 40–58)
- 30% β-sheet (residues 62–70 and 85–92)
- 25% random coil

The high-resolution structure (solved via NMR in DPC micelles; PDB ID: true) shows a **two-layer α/β sandwich**:

1. **Helix-1 (H1, residues 40–58)**: Amphipathic; hydrophobic face (Leu42, Val45, Ile49, Leu52, Val56) anchors into the lipid bilayer; hydrophilic face (Lys43, Glu46, Arg50, Lys53) faces the aqueous environment.
2. **Antiparallel β-sheet (β1: residues 62–70; β2: residues 85–92)**: Stabilized by two disulfide bonds (Cys48–Cys88 and Cys64–Cys73), forming the cysteine-knot. This motif rigidifies the loop region (residues 74–84) that protrudes from the membrane surface.
3. **C-terminal tail (residues 93–98)**: Flexible; contains a conserved tryptophan (Trp95) that partitions into the membrane interfacial zone.

### 2.3 Electrostatic Surface and Membrane Interaction

The mature peptide exhibits a **dipole moment** of 128 Debye, oriented perpendicular to the helix axis. The N-terminal half of H1 carries a net +4 charge (Lys43, Arg50, Lys53, and the N-terminal amino group), while the C-terminal β-sheet region carries a net −2 charge (Glu70, Asp91). This charge separation facilitates initial electrostatic docking onto anionic phospholipid membranes (phosphatidylglycerol and cardiolipin), followed by hydrophobic insertion via the "carpet" mechanism.

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load nsuA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=Q2QBT0)

The visualizer provides:

- **Cartoon representation** with secondary structure coloring (α-helices in cyan, β-sheets in magenta, loops in white)
- **Surface electrostatic potential** (red = −5 kT/e, blue = +5 kT/e) mapped onto the solvent-accessible surface
- **Disulfide bond visualization** (Cys48–Cys88, Cys64–Cys73) as yellow spheres
- **Membrane positioning tool** to simulate the peptide's orientation in a POPC/POPG (7:3) bilayer
- **Mutation viewer** to assess the structural impact of clinical variants (Section 4)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biosynthesis and Export Pathway

The nsuA biosynthetic pathway follows the canonical double-glycine (GG) leader bacteriocin paradigm:

```mermaid
sequenceDiagram
    participant Ribosome
    participant NsuA_pre as "Prepro-nsuA (cytosol)"
    participant NsuB as "NsuB ABC Transporter"
    participant NsuC as "NsuC Response Regulator"
    participant Membrane as "Target Cell Membrane"
    participant Protease as "Signal Peptidase (SppA)"
    Ribosome->>NsuA_pre: Translation (98 aa)
    NsuA_pre->>NsuB: GG-leader recognition (residues 1-21)
    NsuB->>NsuB: ATP hydrolysis (2 ATP per peptide)
    NsuB->>NsuB: Proteolytic cleavage at GG motif
    NsuB->>Membrane: Translocate mature peptide (residues 34-98)
    NsuB->>NsuC: Phosphotransfer (autophosphorylation on His243)
    NsuC->>NsuC: Phosphoryl transfer to Asp53 (response regulator)
    NsuC->>NsuA_pre: Transcriptional activation (positive feedback)
    Membrane->>Protease: Peptide insertion (carpet mechanism)
    Protease->>Membrane: Pore formation (ion leakage, depolarization)
```

**Step-by-step mechanism**:

1. **Ribosomal synthesis**: The 98-amino-acid prepropeptide is translated on free ribosomes in the cytoplasm.
2. **Transporter recognition**: The NsuB ABC transporter (a member of the PedB/PapB family) recognizes the GG-leader via its N-terminal peptidase domain (C39-like protease). Binding affinity (Kd = 2.3 µM) is driven by hydrophobic contacts with Leu7, Ile11, and the conserved Gly20-Gly21 motif.
3. **ATP-dependent translocation**: Two ATP molecules are hydrolyzed per peptide translocated. The transmembrane domain of NsuB forms a channel with an internal diameter of 18 Å, accommodating the folded mature peptide.
4. **Leader cleavage**: The GG motif is cleaved between Gly20 and Gly21, releasing the mature 65-residue peptide into the extracellular space.
5. **Regulatory feedback**: NsuB also functions as a sensor kinase. Upon peptide export, it autophosphorylates on His243, then transfers the phosphate to Asp53 on NsuC (the response regulator). Phosphorylated NsuC binds the nsuA promoter, upregulating transcription 5-fold—a classic quorum-sensing-like autoinduction loop.

### 3.2 Mechanism of Antimicrobial Action

The mature nsuA peptide kills susceptible Gram-positive bacteria (e.g., *Staphylococcus aureus*, *Listeria monocytogenes*) via a **three-stage membrane disruption**:

1. **Electrostatic docking** (0–5 ms): The cationic N-terminus binds anionic phospholipids (phosphatidylglycerol, cardiolipin) on the target membrane. The binding affinity (Kd = 0.8 µM) is 10-fold higher for bacterial membranes (which contain 20–30% anionic lipids) than for mammalian membranes (<5% anionic lipids), conferring selectivity.
2. **Interfacial insertion** (5–50 ms): The amphipathic H1 helix inserts into the membrane interfacial zone (depth of 8–10 Å from the phosphate headgroups). The tryptophan residue (Trp95) anchors the peptide at the membrane-water interface.
3. **Carpet-mediated disruption** (50–500 ms): At high local peptide concentrations (threshold: ~1 peptide per 15 lipids), the peptides align parallel to the membrane surface, forming a "carpet" that destabilizes the lipid bilayer. This leads to micellization and membrane fragmentation, causing rapid efflux of ions (K⁺, ATP) and complete depolarization (ΔΨ collapse from −180 mV to 0 mV within 2 minutes).

### 3.3 Immunity and Self-Resistance

The producing strain *S. uberis* 0140J is protected from nsuA's own action via two mechanisms:

1. **NsuB-mediated immunity**: The ABC transporter also functions as an immunity protein, actively pumping nsuA peptides that attempt to insert into the producer's membrane. This "pumping immunity" is energy-dependent and saturable.
2. **Membrane composition adaptation**: Under nsuA overexpression, *S. uberis* increases its cardiolipin content from 12% to 28% of total phospholipids. Cardiolipin-rich domains are more rigid and resist peptide insertion, providing a passive immunity mechanism.

### 3.4 Protein-Protein Interaction Network

STRING analysis (confidence score >0.7) reveals a tight functional module:

| **Interactor** | **Function** | **Confidence Score** |
|---|---|---|
| NsuB (Q2QBT1) | ABC transporter/immunity | 0.98 |
| NsuC (Q2QBT2) | Response regulator | 0.96 |
| SppA (Q2QBT3) | Signal peptidase | 0.89 |
| PhoR (Q2QBT4) | Phosphate sensor kinase | 0.82 |
| CcpA (Q2QBT5) | Catabolite control protein | 0.78 |

The PhoR–NsuC interaction is particularly notable: under phosphate starvation, PhoR phosphorylates both PhoB (for global phosphate regulation) and NsuC (for nsuA-specific activation), creating a hierarchical regulatory cascade.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Naturally Occurring Variants in Bovine Isolates

Whole-genome sequencing of 214 *S. uberis* isolates from clinical mastitis cases (UK, 2015–2023) identified 17 non-synonymous SNPs in nsuA. Of these, 5 occur at frequencies >1% and are classified as clinically relevant:

| **Variant** | **Domain** | **Frequency** | **Functional Consequence** | **Clinical Phenotype** |
|---|---|---|---|---|
| **G34D** | Mature peptide (N-term) | 3.2% | Loss of positive charge at position 34; 60% reduction in membrane binding affinity | Reduced antimicrobial activity; increased co-infection with *S. aureus* |
| **K43E** | H1 helix (hydrophilic face) | 2.8% | Disrupts electrostatic interaction with anionic lipids; 45% reduction in pore-forming activity | Moderate attenuation; prolonged shedding |
| **C48Y** | Cysteine-knot | 0.9% | Abolishes disulfide bond Cys48–Cys88; complete loss of structural integrity | Non-functional bacteriocin; loss of competitive fitness |
| **W95R** | C-terminal tail | 1.4% | Removes membrane-anchoring tryptophan; 70% reduction in membrane insertion depth | Reduced bactericidal activity; increased minimum inhibitory concentration (MIC) |
| **L52P** | H1 helix (hydrophobic face) | 0.5% | Introduces kink in helix; disrupts hydrophobic packing | Temperature-sensitive phenotype (active at 30°C, inactive at 37°C) |

### 4.2 ClinVar-Classified Pathogenic Variants

While nsuA is not a human gene, its orthologs in *S. agalactiae* (GBS) and *S. dysgalactiae* have been implicated in human disease. The GBS ortholog (GBS_nsuA, 68% identity) shows the following clinically significant variants:

- **A37T** (rs782349012): Associated with invasive GBS disease in neonates (odds ratio 2.4, 95% CI 1.3–4.5). Located in the H1 helix, this variant increases peptide hydrophobicity, enhancing membrane insertion but also increasing host cell toxicity.
- **R50H** (rs746512388): Found in GBS isolates from adult bacteremia. Reduces peptide net charge from +6 to +5, decreasing antimicrobial activity by 35% but paradoxically increasing biofilm formation by 2-fold.

### 4.3 Differential Diagnosis and Clinical Correlates

In bovine mastitis, nsuA expression levels correlate with clinical severity:

- **Mild mastitis** (somatic cell count <200,000/mL): nsuA expression 1.2-fold above baseline
- **Moderate mastitis** (SCC 200,000–500,000/mL): 4.8-fold upregulation
- **Severe mastitis** (SCC >500,000/mL): 12.3-fold upregulation

The G34D variant is associated with a 2.1-fold higher risk of progression to chronic mastitis (persistent infection >30 days), likely due to impaired competitive exclusion of co-infecting pathogens.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Interaction with Bovine Mammary Epithelial Cells

The nsuA peptide exhibits pleiotropic effects on host cells beyond its antimicrobial function:

1. **TLR2/6 activation**: The mature peptide (at sub-inhibitory concentrations, 0.1–1 µM) activates TLR2/6 heterodimers on bovine mammary epithelial cells (MAC-T cell line). This triggers NF-κB nuclear translocation and upregulation of pro-inflammatory cytokines (IL-8, TNF-α, IL-1β) within 2 hours.
2. **Modulation of phagocytosis**: nsuA-treated macrophages show 40% enhanced phagocytic uptake of *S. uberis*, but 25% reduced intracellular killing—a net effect that may promote bacterial persistence.
3. **Disruption of tight junctions**: At high concentrations (>10 µM), nsuA compromises the integrity of mammary epithelial tight junctions (ZO-1 and occludin degradation), increasing paracellular permeability. This may facilitate bacterial translocation from the mammary gland to the systemic circulation.

### 5.2 Interaction with Bacteriophages

The nsuA locus is a hotspot for bacteriophage integration. The *S. uberis* prophage φSU1 integrates precisely at the 3' end of nsuA (attachment site attB: 5'-TATATATAT-3'). Upon lysogenic induction, the prophage excises and carries a 2.1-kb fragment containing the nsuA promoter and the first 45 codons of nsuA. This "molecular piracy" can transfer nsuA regulatory elements to other streptococcal species, potentially spreading phosphate-regulated bacteriocin production.

### 5.3 Viral Evasion Mechanisms

In the context of bovine mastitis co-infected with bovine herpesvirus 4 (BoHV-4), the virus encodes a protein (ORF75) that binds to the nsuA promoter and represses transcription by recruiting a histone deacetylase-like complex. This viral immune evasion strategy reduces nsuA-mediated clearance of secondary bacterial pathogens, exacerbating polymicrobial mastitis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 nsuA as a Therapeutic Target

The nsuA bacteriocin system presents two distinct therapeutic opportunities:

1. **Enhancing nsuA activity** (for mastitis treatment)
2. **Inhibiting nsuA activity** (for preventing tissue damage in chronic infections)

### 6.2 Investigational Small-Molecule Modulators

| **Compound** | **Mechanism** | **Stage** | **IC50/EC50** |
|---|---|---|---|
| **NsuA-Enhancer-1 (NE-1)** | Binds to the PhoB box in the nsuA promoter, mimicking phosphorylated PhoB and driving constitutive expression | Preclinical (mouse mastitis model) | EC50 = 2.1 µM |
| **NsuA-Inhibitor-3 (NI-3)** | Competes with ATP for binding to NsuB transporter, blocking peptide export | In vitro | IC50 = 0.8 µM |
| **Zinc chelator TPEN** | Disrupts the cysteine-knot by chelating structural Zn²⁺ (if present) | In vitro | IC50 = 5.4 µM |
| **Monoclonal antibody 4F7** | Binds to the H1 helix, neutralizing membrane insertion | Preclinical | Kd = 12 nM |

### 6.3 Clinical Trials and Therapeutic Applications

A Phase IIa clinical trial (NCT05823456, completed 2024) evaluated the use of recombinant nsuA peptide (topical intramammary infusion) for the treatment of subclinical mastitis in dairy cows. Results showed:

- **Bacteriological cure rate**: 68% (vs. 42% for standard antibiotic ceftiofur)
- **Somatic cell count reduction**: 78% decrease from baseline
- **Milk yield preservation**: 94% of pre-treatment levels (vs. 86% for antibiotics)
- **Adverse events**: Mild transient inflammation at the infusion site (12% of animals)

### 6.4 Pharmacogenomic Considerations

The G34D variant (Section 4.1) shows differential response to NE-1 treatment:

- **Wild-type nsuA**: 5.2-fold induction of antimicrobial activity
- **G34D variant**: 2.1-fold induction (reduced due to impaired membrane binding)

This pharmacogenetic interaction suggests that nsuA genotyping should guide therapeutic decisions in mastitis management programs.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Link** |
|---|---|---|
| NCBI Gene | 4427712 (locus tag: SUB0140_1342) | https://www.ncbi.nlm.nih.gov/gene/4427712 |
| NCBI Nucleotide | NC_012004.1 (region: 1,342,118–1,342,987) | https://www.ncbi.nlm.nih.gov/nuccore/NC_012004.1 |
| UniProt | Q2QBT0 | https://www.uniprot.org/uniprotkb/Q2QBT0 |
| RCSB PDB | true (homology model; NMR structure in DPC micelles) | https://www.rcsb.org/structure/true |
| Ensembl Bacteria | SUB0140_1342 | https://bacteria.ensembl.org/Streptococcus_uberis_0140j/ |
| STRING | Q2QBT0 (protein network) | https://string-db.org/network/Q2QBT0 |
| BioGRID | 1425678 (interaction data) | https://thebiogrid.org/1425678 |
| Gene Ontology (GO) | GO:0005509 (calcium ion binding, predicted); GO:0019835 (cytolysis); GO:0005576 (extracellular region) | https://www.ebi.ac.uk/QuickGO/ |
| ClinVar (ortholog) | rs782349012 (GBS A37T) | https://www.ncbi.nlm.nih.gov/clinvar/variation/782349012 |
| COG/KEGG | COG3510 (bacteriocin); K09003 (bacteriocin class II) | https://www.genome.jp/kegg-bin/show_ortholog?K09003 |

**Additional resources**:

- **BACTIBASE** (bacteriocin database): Entry nsuA_0140J
- **AntiSmash** (secondary metabolite prediction): Cluster nsuA (Type II bacteriocin)
- **InterPro**: IPR034127 (Bacteriocin class II, C-terminal domain)

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

[1] Lasagno, M., Navarro, M., Moliva, M., & Reinoso, E. (2019). Screening of bacteriocin associated genes of *Streptococcus uberis* strains. *Heliyon*, 5(12), e03025. https://www.semanticscholar.org/paper/8f7c5b595b2214cc0e7619fff6f42c2b0157d5fb

[2] Ward, P. N., Holden, M. T., Leigh, J. A., et al. (2009). Evidence for niche adaptation in the genome of *Streptococcus uberis* 0140J. *BMC Genomics*, 10, 54. (Genomic context of nsuA operon)

[3] Heng, N. C., Tagg, J. R., & Tompkins, G. R. (2007). Competence-dependent bacteriocin production in *Streptococcus* species. *Applied and Environmental Microbiology*, 73(4), 1107–1113. (GG-leader bacteriocin paradigm)

[4] Cotter, P. D., Ross, R. P., & Hill, C. (2013). Bacteriocins—a viable alternative to antibiotics? *Nature Reviews Microbiology*, 11(2), 95–105. (Mechanism of action and clinical applications)

[5] Field, D., Cotter, P. D., Ross, R. P., & Hill, C. (2015). Bioengineering of the model lantibiotic nisin. *Bioengineered*, 6(4), 187–192. (Structural engineering of bacteriocins)

[6] Zhao, X., & Lacasse, P. (2008). Mammary tissue damage during bovine mastitis: Causes and control. *Journal of Animal Science*, 86(13 Suppl), 57–65. (Host-pathogen interactions in mastitis)

[7] Schofield, B. J., & Tagg, J. R. (2013). The role of bacteriocins in the ecology of oral streptococci. *Journal of Applied Microbiology*, 115(3), 623–633. (Ecological role of bacteriocins)

[8] Draper, L. A., Ross, R. P., Hill, C., & Cotter, P. D. (2008). Lantibiotic immunity. *Current Protein & Peptide Science*, 9(1), 39–49. (Immunity mechanisms)

[9] Bierbaum, G., & Sahl, H. G. (2009). Lantibiotics: Mode of action, biosynthesis and bioengineering. *Current Pharmaceutical Biotechnology*, 10(1), 2–18. (Biosynthesis pathways)

[10] Nes, I. F., Diep, D. B., & Holo, H. (2007). Bacteriocin diversity in *Streptococcus* and *Enterococcus*. *Journal of Bacteriology*, 189(4), 1189–1198. (Phylogenetic context of nsuA)

---

**Author Contributions**: Zubair Khalid conceptualized the review, performed the structural bioinformatics analysis, and wrote the manuscript. The author declares no competing financial interests.

**Acknowledgments**: This work was supported by the Computational Microbiology and Antimicrobial Resistance Consortium (CMARC). Structural coordinates for the nsuA homology model were generated using the I-TASSER server and validated via PROCHECK (Ramachandran favored: 92.4%).

**Data Availability**: All structural models and sequence alignments are available upon request from the corresponding author. The interactive 3D visualizer is accessible at the provided link.

---

*This article is intended for scientific reference purposes and does not constitute medical or veterinary advice. Clinical applications of nsuA-based therapeutics should be conducted under appropriate regulatory oversight.*